APC-Labeled Human CLEC12A / MICL / CLL-1 Protein, His Tag, premium grade (Site-specific conjugation)

Cat. No. / Size
Price
Qty
CLA-HA246-25tests
$470.00
CLA-HA246-200tests
$2920.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    CLEC12A, MICL, CLL-1, CLL1, DCAL2, DCAL-2, CD371

  • Source

    APC-Labeled Human CLEC12A Protein, His Tag, premium grade (CLA-HA246) is produced via conjugation of APC to Human CLEC12A Protein, His Tag, premium grade with a new generation site-specific technology under optimal conditions with a proprietary technology. Human CLEC12A Protein, His Tag, premium grade is expressed from human 293 cells (HEK293). It contains AA His 65 - Ala 265 (Accession # Q5QGZ9-2).

    Predicted N-terminus: Gly

    It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

    Request for sequence

  • Molecular Characterization

    CLEC12A Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 27.3 kDa.

  • Conjugate

    APC

    Excitation Wavelength: 640 nm

    Emission Wavelength: 661 nm

  • Application

    Please note that this product is NOT compatible to streptavidin detection system.

  • Endotoxin

    Less than 0.1 EU per test by the LAL method / rFC method.

  • Sterility

    Negative

  • Mycoplasma

    Negative

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, 0.5% rHSA, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 24 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution;
    3. 2-8°C for 12 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Bioactivity-FACS

     CLEC12A FACS

    5e5 of Anti-CLEC12A/CLL-1 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human CLEC12A Protein, His Tag, premium grade (Cat. No. CLA-HA246) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).

    Protocol

Customer Reviews
Writing Reviews

Background

CLEC12A (C-type lectin domain family 12 member A) is also known as CLL1, DCAL2, MICL. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases. Evidence of distinct disease propagating stem cells in myelodysplastic syndrome (MDS) has emerged in recent years. The role of CLEC12A in MDS, however, remains to be elucidated. Furthermore, CLEC12A has been proposed as a promising marker of leukaemic stem cells in AML.

Recent Advances

 
Drug Development Progress
  • English Name:

    C-Type lectin domain family 12 member A

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    26 Details

  • Highest Development Stage:

    Phase 2 Clinical

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8